LC16m8: an attenuated smallpox vaccine (Q36628965)

15 August 2017

1 reference

title

LC16m8: an attenuated smallpox vaccine (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

Julie Kenner

1 reference

15 August 2017

Fiona Cameron

1 reference

15 August 2017

Cyril Empig

1 reference

15 August 2017

David V Jobes

1 reference

15 August 2017

Marc Gurwith

1 reference

15 August 2017

language of work or name

English

0 references

publication date

21 April 2006

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

issue

47-48

1 reference

15 August 2017

page(s)

7009-7022

1 reference

Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Modified vaccinia Ankara: potential as an alternative smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

FURTHER STUDIES OF THE INFECTIOUS UNIT OF VACCINIA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Immunologic responses to vaccinia vaccines administered by different parenteral routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

IMMUNOGENICITY OF ULTRAVIOLET-IRRADIATED, NON-INFECTIOUS, VACCINIA-VIRUS VACCINE IN INFANTS AND YOUNG CHILDREN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Stability of recombinant vaccinia virus LC16m0 or LC16m8: preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

The formation and function of extracellular enveloped vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Duration of antiviral immunity after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Poxvirus immunomodulatory strategies: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Vaccinia virus: a selectable eukaryotic cloning and expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Analysis of canine herpesvirus gB, gC and gD expressed by a recombinant vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Long-term protective immunity to rinderpest in cattle following a single vaccination with a recombinant vaccinia virus expressing the virus haemagglutinin protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Developing new smallpox vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Adsorption and fluorescence of fat-soluble fluorescent dyes on class I and class III Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

An antigenic difference between intracellular and extracellular rabbitpox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Myopericarditis following smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Biodefense. Smallpox vaccines: looking beyond the next generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Clonal vaccinia virus grown in cell culture as a new smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

The Future of Smallpox Vaccination: is MVA the key?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Smallpox vaccination: Risk considerations for patients with atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Bioterrorism. Smallpox vaccinations: how much protection remains?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Smallpox in Europe, 1950-1971

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

The persistence of neutralizing antibodies after revaccination against smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Responses to smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

Functional Analysis of Vaccinia Virus B5R Protein: Essential Role in Virus Envelopment Is Independent of a Large Portion of the Extracellular Domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.087

7 January 2021

inferred from DOI database lookup

Induction of neutralizing antibodies against bovine leukosis virus in rabbits by vaccination with recombinant vaccinia virus expressing bovine leukosis virus envelope glycoprotein

1 reference

12 December 2020

Primary vaccination with an attenuated strain of vaccinia virus

1 reference

12 December 2020

Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.

1 reference

12 December 2020

Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus

1 reference

12 December 2020

Clinical and immunological study of percutaneous revaccination in children who originally received smallpox vaccine subcutaneously

1 reference

12 December 2020

Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78)

1 reference

12 December 2020

Laboratory and vaccination studies with dried smallpox vaccines

1 reference

12 December 2020

Adventitious agents and smallpox vaccine in strategic national stockpile

1 reference

12 December 2020

Rabbit pox: an experimental study of the pathways of infection in rabbits

1 reference

12 December 2020

[Virulence and immunogenicity of a modified vaccinia virus (strain MVA) (author's transl)]

1 reference

12 December 2020

New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

1 reference

12 December 2020

Studies with dried and glycerinated smallpox vaccines of full and diminished potencies

1 reference

12 December 2020

[Immunomodulatory proteins of orthopoxviruses]

1 reference

12 December 2020

Smallpox vaccination of eczema patients with attenuated live vaccinia virus

1 reference

12 December 2020

Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene

1 reference

12 December 2020

Human cytotoxic T-cell memory: long-lived responses to vaccinia virus

1 reference

12 December 2020

An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)

1 reference

12 December 2020

10.1016/J.VACCINE.2006.03.087

Identifiers

DOI

1 reference

15 August 2017

0 references

1 reference